BRIDGE BIOTHERAPEUTICS, INC.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 2015-01-01

Employees: 42

Market Cap: -

Website: http://www.bridgebiorx.com

Clinical Trials

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Phase 1

Recruiting

Conditions: EGFR Mutant Advanced Non-Small Cell Lung Cancer

Interventions: Drug: BBT-207

First Posted Date: 2023-06-27

Last Posted Date: 2024-12-12

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 92

Registration Number: NCT05920135

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 1 locations

To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

Phase 2

Active, not recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: BBT-877

First Posted Date: 2022-08-02

Last Posted Date: 2024-08-13

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 129

Registration Number: NCT05483907

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇦🇺
Institute for Respiratory Health, Nedlands, Western Australia, Australia
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 41 locations

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Phase 1

Terminated

Conditions: NSCLC

Interventions: Drug: BBT-176

First Posted Date: 2021-03-29

Last Posted Date: 2023-12-14

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 45

Registration Number: NCT04820023

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 1 locations

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: BBT-401-1S or Placebo

First Posted Date: 2020-10-22

Last Posted Date: 2023-09-07

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 38

Registration Number: NCT04596293

Locations: 🇺🇸
Premier Gastroenterology, Little Rock, Arkansas, United States
🇺🇸
Saini Surinder S MD, Fountain Valley, California, United States
🇺🇸
Gastro Care Institute, Lancaster, California, United States

and more 26 locations

Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Phase 1

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: BBT-401-1S

First Posted Date: 2020-07-21

Last Posted Date: 2021-10-01

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 2

Registration Number: NCT04478825

Locations: 🇳🇿
P3 Research, Wellington, New Zealand

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BBT-877 single dose
Drug: Placebo single dose

First Posted Date: 2019-10-25

Last Posted Date: 2020-01-18

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT04138849

Locations: 🇺🇸
WCCT, Cypress, California, United States

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BBT-877
Drug: Itraconazole
Drug: Midazolam
Drug: Esomeprazole

First Posted Date: 2019-10-25

Last Posted Date: 2020-01-18

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 48

Registration Number: NCT04138836

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BBT-877, Single dose
Drug: Placebo group
Drug: BBT-877, Multiple doses

First Posted Date: 2019-02-05

Last Posted Date: 2020-01-18

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 88

Registration Number: NCT03830125

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: BBT-401-1S first and then Placebo
Drug: Placebo first and then BBT-401-1S

First Posted Date: 2019-01-11

Last Posted Date: 2022-03-21

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 16

Registration Number: NCT03800420

Locations: 🇺🇸
Site 13, McAllen, Texas, United States
🇺🇸
Site 11, Boca Raton, Florida, United States
🇺🇸
Site 12, Pembroke Pines, Florida, United States

and more 8 locations

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Phase 1

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: BBT-401-1S, Single dose
Drug: BBT-401-1S, Multiple doses
Drug: Placebo

First Posted Date: 2018-03-29

Last Posted Date: 2021-07-21

Lead Sponsor: Bridge Biotherapeutics, Inc.

Target Recruit Count: 80

Registration Number: NCT03482648

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy